Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of AK117 in intermediate- to high-risk myelodysplastic syndrome
CTR20210825Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in myelodysplastic syndrome (MDS), sponsored by Akeso, Inc.. Started Jun 2021; status: completed.
02
Drugs
ligufalimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20210825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210825.